Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®

Summary

The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in healthy subjects between 18 and 50 years of age.

Timeline

Start

2017-11-27

Primary completion

2017-12-22

Completion

2017-12-22

Drugs

Indications